Background and Objectives: The objective was to compare the rate of onset of diabetes mellitus (DM) in patients with atrial fibrillation (AF) as compared with atrial flutter (AFL).

Methods: The incidence of DM through the national cohort registry in 14,014 newly diagnosed AF and 14,014 newly diagnosed AFL was investigated. Propensity score matching was used to optimize comparability between these 2 groups. Further analysis with Cox model, Kaplan-Meier methods and competing risk analysis were used to compare the incidence of DM in patients with AF and AFL.

Results: The overall incidence of diabetes was higher among cases in AF cohort (1,653 diabetes cases, 11.7%) than in AFL cohort (1,448 diabetes cases, 10.3%). The risk of diabetes was 1.17-fold greater in the AF cohort compared with that in the AFL cohort (95% confidence interval [CI], 1.09–1.25; p<0.001). After adjustment for all relevant confounding factors in the competing risk regression model, the risk of diabetes remained significantly increased 1.16-fold in the AF cohort (95% CI, 1.09–1.25; p<0.001).

Conclusions: The message of higher incidence rate of DM in patients with AF compared to those with AFL was delivered in this study.

Keywords: Atrial fibrillation; Atrial flutter; Diabetes mellitus

INTRODUCTION

In the aging society, the incidence of diabetes mellitus (DM) and atrial arrhythmia is increasing.1-4 DM, although once was thought to be an endocrine disorder, has been well established as some kind of vascular disorder.5-7 Impact of atrial arrhythmia on cardiovascular diseases was clearly documented; and the underlying mechanisms were complex, among them, atrial arrhythmia triggering vascular inflammation was one of the proposed theories.8-10 Based upon current knowledge, atrial arrhythmia might be only one of several markers for an increased risk of ischemic events.
Since DM and atrial arrhythmia are likely all part of the same pattern of vascular biology and given the growing number of patients with atrial arrhythmia, it would be of importance if the data were robust enough to make a distinction between atrial fibrillation (AF) and atrial flutter (AFL), the 2 common atrial arrhythmias, for the subsequent DM risk per preventive medical point of view. As such the distinction between AF and AFL is affected by the fact that management of the two conditions remains similar and many patients with AFL tend to convert to AF at some point.

From Taiwanese large national database, data from patients with AF/AFL hospitalization between 2000 and 2013 were collected, with a population of 28,028 study participants. This is an impressive data set with long-term outcomes that are not available in randomized controlled trials. Moreover, propensity score matching was used to eliminate differences in age, sex, comorbidities in this register-based, observational study on the comparative association of AF/AFL and DM.

## METHODS

### Data source

This study was a secondary data analysis that adopted a sample of all beneficiaries who were retrieved from Taiwan’s National Health Insurance Research Database (NHIRD). NHIRD was built by the National Health Research Institute which contains 23 million National Health Insurance (NHI) enrollees. More than 20,000 medical care facilities, including hospitals, clinics, pharmacies, which represent over 93% of all healthcare facilities in Taiwan, were contracted by the NHI project. Under the universal health coverage project, virtually all healthcare services, including medical facility registries, medication prescriptions, and outpatient, inpatient, and emergency visiting data for Taiwan’s general public were collected. This study investigated the risk of new onset of DM among patients with AF or AFL, using the inpatients file from NHIRD. This study was approved by the Ethics Review Board of China Medical University (CMUH-104-REC2-i15).

### Sample participant

The diagnostic code of NHIRD in Taiwan is based upon the International Classification of Diseases, Ninth Clinical Modification (ICD-9-CM). We selected a cohort of AF patients with ICD-9-CM code 427.31 who had an inpatient visit and a comparable cohort of patients with AFL (ICD-9-CM code 427.32). The index date was defined as the earliest time of a diagnose of either AF or AFL. Both cohorts were followed until the diagnosis of diabetes, withdrawal from this program, death or at the end of the study period (December 31, 2013), whichever came first. We also excluded those with a diagnosis of diabetes before the entry time of the study. Finally, we used propensity score matching to select 14,014 patients with AF and 1-fold corresponding amount of AFL cohort by age of index date, sex, comorbidities and index year.

### Outcome and comorbidity

The end point in this study was newly diagnosed diabetes (ICD-9-CM code 250.x0 and 250.x2). We also analyzed diabetes-associated comorbidities, including abnormal liver function, hypertension, hyperlipidemia, coronary artery disease (CAD), congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), autoimmune disease, gout, peripheral arterial occlusion disease (PAOD), chronic kidney disease (CKD), and stroke. Comorbidities were identified before the index date.
Statistical analysis

Propensity score matching was used to optimize the comparability between 2 cohorts. The propensity score was estimated for each patient by a non-parsimonious multivariable logistic regression, with receipt of disease status as the dependent variable. Age, sex, comorbidities and index year were independent variables for matching between these 2 cohorts. Demographic characteristics and the prevalence of comorbidities were compared by $\chi^2$ test and t-test between the two cohorts. Incidence density of diabetes according to person-years in each cohort were calculated. Multivariate models were simultaneously adjusted for covariables found significantly associated with diabetes in the univariable models. The Cox model was used to calculate the adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) to compare the risk of diabetes in the AF cohort relative to the AFL cohort. The Fine and Gray model, which extends the univariate and multivariate Cox proportional-hazard regression model, were used to estimate the subhazard ratios (SHRs) of diabetes by considering death as a competing risk. Cumulative incidence curves of diabetes for AF cohort and AFL cohort were assessed using Kaplan-Meier analysis, and the differences between the cohorts were evaluated by the log-rank test. All analyses were performed using SAS software (version 9.4 for windows; SAS Institute, Cary, NC, USA). A 2-tailed p value < 0.05 was considered to indicate the statistical significance.

RESULTS

After propensity score matching, we identified 14,014 patients with AF and an identical number with AFL, with arrhythmias diagnosed between January 1, 2000 and December 31, 2012. The matched pairs were similar with regard to all covariables which including age, sex, abnormal liver function, hypertension, hyperlipidemia, CAD, CHF, COPD, autoimmune disease, gout, PAOD, CKD, and stroke. (Table 1)

Table 1. Baseline characteristics of hospitalized patients, by the presence of with AF and with AFL, and after matching for propensity score

| Variables               | AF (n=14,014) | AFL (n=14,014) | p value |
|-------------------------|---------------|----------------|---------|
| Age (years)             |               |                |         |
| ≤49                     | 1,743 (12.4)  | 1,878 (13.4)   | 0.016   |
| 50–64                   | 3,033 (21.6)  | 2,894 (20.7)   |         |
| ≥65                     | 9,238 (65.9)  | 9,242 (66.0)   |         |
| Mean±SD*                | 68.8±14.9     | 68.7±15.6      | 0.593   |
| Sex                     |               |                | 0.540   |
| Female                  | 4,924 (35.1)  | 4,973 (35.5)   |         |
| Male                    | 9,090 (64.9)  | 9,041 (64.5)   |         |
| Comorbidity             |               |                |         |
| Abnormal liver function | 2,061 (14.7)  | 2,106 (15.0)   | 0.450   |
| Hypertension            | 6,916 (49.4)  | 6,962 (49.7)   | 0.583   |
| Hyperlipidemia          | 1,101 (10.8)  | 1,470 (10.5)   | 0.427   |
| CAD                     | 5,396 (38.5)  | 5,319 (38.0)   | 0.344   |
| CHF                     | 4,693 (33.5)  | 4,612 (32.9)   | 0.304   |
| COPD                    | 2,685 (19.2)  | 2,633 (18.8)   | 0.428   |
| Autoimmune disease      | 897 (6.40)    | 854 (6.09)     | 0.289   |
| Gout                    | 1,166 (8.32)  | 1,146 (8.18)   | 0.664   |
| PAOD                    | 560 (4.00)    | 562 (4.01)     | 0.951   |
| CKD                     | 660 (4.71)    | 636 (4.54)     | 0.495   |
| Stroke                  | 3,251 (23.2)  | 3,168 (22.6)   | 0.238   |

AF = atrial fibrillation; AFL = atrial flutter; CAD = coronary artery disease; CHF = congestive heart failure; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; PAOD = peripheral arterial occlusion disease; SD = standard deviation. $\chi^2$ test; *t-test.
Table 2. Incidence and HR or SHR of diabetes in patients with AF compared to those with AFL

| Outcome | AF (n=14,014) | AFL (n=14,014) | Compared to AFL |
|---------|---------------|----------------|----------------|
|         | Event PY Rate | Event PY Rate  | Crude HR (95% CI) | Adjusted HR\(^*\) (95% CI) | Crude SHR (95% CI) | Adjusted SHR\(^*\) (95% CI) |
| Overall | 1,653 58,885 28.1 | 1,448 60,642 23.9 | 1.17 (1.09–1.26)\(^*\) | 1.17 (1.09–1.25)\(^*\) | 1.16 (1.08–1.25)\(^*\) | 1.16 (1.09–1.25)\(^*\) |

Rate, crude HR, and crude SHR are presented as incidence rate (per 1,000 person-years), relative hazard ratio, and relative subhazard ratio, respectively. AF = atrial fibrillation; AFL = atrial flutter; CAD = coronary artery disease; CHF = congestive heart failure; CI = confidence interval; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; HR = hazard ratio; PY = person-years; SHR = subhazard ratio. \(^*\)p<0.001. Covariables found significantly associated with diabetes in the univariable Cox proportional regression model were further examined by the multivariable Cox proportional regression model (including abnormal liver function, hypertension, CAD, CHF, COPD, gout, CKD, and stroke). Covariables found significantly associated with diabetes in the univariable competing-risks regression model were further examined by the multivariable Competing-Risks Regression Model (including abnormal liver function, hypertension, CAD, CHF, COPD, gout, CKD, and stroke).

DISCUSSION

This study investigated the association between new onset DM with 2 common atrial arrhythmias, AF and AFL, using the database of a population-based large-scale cohort study of the inpatients enrolled in the Taiwan NHI program. The major advantage of this study is clearly that using a nation-wide database there is little bias in terms of prevalence which is
usually present in studies performed in tertiary centers. Moreover, sample size was large with 14,014 AF patients and 14,014 AFL patients, and AF has a stronger association than the AFL with regard to new onset DM was concluded.

Atrial arrhythmia is a heterogeneous disorder, and there are certain differences between patient populations with AF and AFL involvement of the pathological process. Given the increasing burden of DM for major morbidity and mortality, it is of clinical relevance to establish the relationship between DM and 2 common atrial arrhythmias. While baseline characteristic might modify the association between AF/AFL and incident DM, both cohorts were propensity scoring matching with the covariates considering risk component of DM to alleviate the concern about the strength of each covariate to predict the incident DM and the trend of DM risk increase in these two atrial arrhythmias is evident from this analysis. Although the analysis with large-scale national data enables to detect the risk differences among each stratum with enough power, and the difference is statistically significant, the actual difference is considered as modest since the adjusted HR and adjusted SHR were 1.17 and 1.16, respectively.

DM is a common comorbidity in atrial arrhythmia. Association of atrial arrhythmias and DM is given as an established fact. DM and chronic arrhythmia management has improved such that patients are living longer before dying from the underlying heart diseases. As a result, DM appears to be one of the fastest growing causes of morbidity and mortality in clinical practice. While the difference between the 2 study cohorts might be explained by a higher degree of ventricular disease with cardio-endocrinology interactions in the AF group is a plausible theory. Further large scales mechanism-exploring studies are expected to explore this research question.

First, this research applied the method of cohort study, but the time of hospitalization in enrolled patients was widely ranged. During the study period, standard treatment or trend of intervention for AF/AFL might be possibly changed. Second, diagnoses were retrieved from only inpatient files, and many patients with asymptomatic AF/AFL and acceptable heart rate were managed as outpatients. In addition, in this study, data regarding the use of Holter electrocardiogram was also unavailable, and it should also be listed as the limitation of research since transient AF/AFL cannot be registered. Moreover, although the long follow-up period allowed accumulation of outcome events, the chance of switching exposure status (AF to AFL, or AFL to AF) and unbalanced censoring also increases with longer follow-up period, thus it may introduce bias which are not controllable by the current analysis. Finally, some of the concerns which remain with the observational study design should also be mentioned. Furthermore, the inherent limitations of national administrative database use with no information on biological data and the need to rely on ICD-9-CM codes that may be very partial might also be acknowledged.

The message of higher incidence rate of DM in patients with AF compared to those with AFL was delivered in this study.

REFERENCES

1. Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. _Lancet_ 2010;375:2215-22.

_PUBMED_ | _CROSSREF_
2. 2014 United States Renal Data System Annual Data Report: Epidemiology of kidney disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2014. p.188-210.

3. Staerk L, Shener JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res 2017;120:1501-17.

4. Chugh SS, Havmoeller R, Narayan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129:837-47.

5. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J 2013;34:2436-43.

6. Lüscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Circulation 2003;108:1655-61.

7. Sowers JR. Diabetes mellitus and vascular disease. Hypertension 2013;61:943-7.

8. Oduatyo A, Wong CX, Hsiao AI, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ 2016;354:i4482.

9. Conen D, Chan CL, Glynn RJ, et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA 2011;305:2080-7.

10. Emdin CA, Wong CX, Hsiao AI, et al. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies. BMJ 2016;352:h7013.

11. Bohne LJ, Johnson D, Rose RA, Wilton SB, Gillis AM. The association between diabetes mellitus and atrial fibrillation: clinical and mechanistic insights. Front Physiol 2019;10:135.

12. De Sensi F, De Potter T, Cresti A, Severi S, Breithardt G. Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives. Cardiovasc Diagn Ther 2015;5:364-73.

13. Goudis CA, Korantzopoulos P, Ntalias IV, Kallergis EM, Liu T, Ketikoglou DG. Diabetes mellitus and atrial fibrillation: pathophysiological mechanisms and potential upstream therapies. Int J Cardiol 2015;184:617-22.

14. Serban RC, Scridon A. Data linking diabetes mellitus and atrial fibrillation-how strong is the evidence? From epidemiology and pathophysiology to therapeutic implications. Can J Cardiol 2018;34:1492-502.

15. Mareedu RK, Abdalrahman IB, Dharmarshankar KC, et al. Atrial flutter versus atrial fibrillation in a general population: differences in comorbidities associated with their respective onset. Clin Med Res 2010;8:1-6.

16. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-354.

17. National Health Research Institutes (TW). National Health Insurance Research Database [Internet]. Zhunan: National Health Research Institutes; c2020 [cited 2015 Apr 14]. Available from http://nhird.nhri.org.tw/en/index.html.

18. Hu WS, Lin CL. Suicide attempt in patients with atrial fibrillation - A nationwide cohort study. Prog Neuropsychopharmacol Biol Psychiatry 2019;92:470-5.

19. Hu WS, Lin CL. CHA2DS2-VASC score in the prediction of ischemic bowel disease among patients with atrial fibrillation: Insights from a nationwide cohort. Int J Cardiol 2017;235:56-60.